Department of Genetics, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands.
Cell. 2010 Aug 20;142(4):601-12. doi: 10.1016/j.cell.2010.07.020.
Fibrillar protein aggregates are the major pathological hallmark of several incurable, age-related, neurodegenerative disorders. These aggregates typically contain aggregation-prone pathogenic proteins, such as amyloid-beta in Alzheimer's disease and alpha-synuclein in Parkinson's disease. It is, however, poorly understood how these aggregates are formed during cellular aging. Here we identify an evolutionarily highly conserved modifier of aggregation, MOAG-4, as a positive regulator of aggregate formation in C. elegans models for polyglutamine diseases. Inactivation of MOAG-4 suppresses the formation of compact polyglutamine aggregation intermediates that are required for aggregate formation. The role of MOAG-4 in driving aggregation extends to amyloid-beta and alpha-synuclein and is evolutionarily conserved in its human orthologs SERF1A and SERF2. MOAG-4/SERF appears to act independently from HSF-1-induced molecular chaperones, proteasomal degradation, and autophagy. Our results suggest that MOAG-4/SERF regulates age-related proteotoxicity through a previously unexplored pathway, which will open up new avenues for research on age-related, neurodegenerative diseases.
纤维状蛋白聚集体是几种不可治愈的、与年龄相关的神经退行性疾病的主要病理学特征。这些聚集体通常包含易于聚集的致病性蛋白质,如阿尔茨海默病中的淀粉样β蛋白和帕金森病中的α-突触核蛋白。然而,人们对这些聚集体在细胞衰老过程中是如何形成的知之甚少。在这里,我们确定了一种进化上高度保守的聚集调节剂 MOAG-4,它是秀丽隐杆线虫多聚谷氨酰胺疾病模型中聚集体形成的正调节剂。MOAG-4 的失活抑制了形成聚集体所必需的紧凑多聚谷氨酰胺聚集中间体的形成。MOAG-4 在驱动聚集中的作用扩展到淀粉样β蛋白和α-突触核蛋白,并且在其人类同源物 SERF1A 和 SERF2 中是进化保守的。MOAG-4/SERF 似乎独立于 HSF-1 诱导的分子伴侣、蛋白酶体降解和自噬而起作用。我们的研究结果表明,MOAG-4/SERF 通过以前未被探索的途径调节与年龄相关的蛋白毒性,这将为与年龄相关的神经退行性疾病的研究开辟新的途径。